About 15%–20% of breast cancers involve the HER2 + receptor, now known as ERBB2 +, and about 15% of breast cancers are triple-negative and do not have ER, PR, or ERBB2 protein in the cancer cells. This evidence concerns the gene ESR1 and breast cancer.